Marinus Pharmaceuticals (MRNS) Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRNS shares.
View MRNS analyst ratings or view top-rated stocks.

9 brokerages have issued 12 month target prices for Marinus Pharmaceuticals' stock. Their MRNS share price forecasts range from $9.00 to $32.00. On average, they predict the company's share price to reach $21.50 in the next year. This suggests a possible upside of 167.1% from the stock's current price.
View analysts price targets for MRNS or view top-rated stocks among Wall Street analysts.

Marinus Pharmaceuticals' stock was trading at $3.98 on January 1st, 2023. Since then, MRNS stock has increased by 102.3% and is now trading at $8.05.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our MRNS earnings forecast.

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) issued its quarterly earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.76) by $0.15. The biopharmaceutical company earned $6.08 million during the quarter, compared to the consensus estimate of $5.14 million. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 139.10% and a negative net margin of 113.01%.

ETFs with the largest weight of Marinus Pharmaceuticals (NASDAQ:MRNS) stock in their portfolio include Simplify Propel Opportunities ETF (SURI) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

Shares of Marinus Pharmaceuticals reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tankers (NAT), The Gabelli Dividend & Income Trust (GDV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Capricor Therapeutics (CAPR), Geron (GERN), Realty Income (O), Advanced Micro Devices (AMD), Novavax (NVAX) and Inovio Pharmaceuticals (INO).

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Shares of MRNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRNS stock can currently be purchased for approximately $8.05.

Marinus Pharmaceuticals (NASDAQ:MRNS) has a market capitalization of $407.41 million and generates $25.48 million in revenue each year. The biopharmaceutical company earns $-19,820,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

The company employs 151 workers across the globe.

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The official website for the company is www.marinuspharma.com. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at lcaperelli@marinuspharma.com, or via fax at 203-315-0565.